Abstract
BackgroundRituximab (RTX) is a safe and effective treatment for rheumatoid arthritis (RA). In The Netherlands, RTX is usually administered intravenously every six months in standard low dose (2x500 mg or...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
